Australia's Amplia Therapeutics falls as HY loss widens
** Shares of Amplia Therapeutics ATX.AX fall 3.6% to A$0.135, on track for their weakest session since November 18 ** The clinical-stage, drug development co's HY loss attributable widens to A$4.2 million ($2.75 million) from A$2.8 million last year ** However, ATX up 21.7% this week, set for its strongest week since July 10 ** Stock up 51.7% YTD ($1 = 1.5300 Australian dollars) (Reporting by Jasmeen Ara Shaikh in Bengaluru) ((Jasmeenaraislam.shaikh@thomsonreuters.com ))
Recent news on Amplia Therapeutics
See all newsBrief: Amplia Therapeutics Signs Collaboration And Supply Agreement With Lilly
Australia's Amplia rises to 4-month high on Eli Lilly cancer drug trial collaboration
Brief: Amplia Therapeutics Says Warwick Tong Will Retire As Board Chairman
Brief: Amplia Therapeutics Reports Four Additional Complete Responses And Improved Overall Survival Data In Accent Pancreatic Cancer Trial
Brief: Amplia Therapeutics Requests Trading Halt Pending Clinical Trial Results Announcement